Published in Cancer Weekly, February 22nd, 2000
Grzegorz Dworacki and colleagues evaluated the efficacy of vaccines consisting of tumor peptide-pulsed bone marrow (BM)-derived dendritic cells (DC) generated in the presence of FBS or BALB/c mouse serum (NMS) in the BALB/c Meth A tumor model.
They reported their findings at the Proceedings of the 1999 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer New Drugs Meeting, held November 16-19, 1999, in Washington, DC. Their study was titled "Murine non-pulsed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.